Figure 5.

Kaplan–Meier curves showing the occurrence of safety communications after medicines’ approval depending on the time taken by the EMA.
, 0–180 days;
, 181–210 days;
, > 210 days

Kaplan–Meier curves showing the occurrence of safety communications after medicines’ approval depending on the time taken by the EMA.
, 0–180 days;
, 181–210 days;
, > 210 days